Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma

被引:0
作者
Shugo Kowata
Yuki Seki
Yasuhiko Tsukushi
Tsuyoshi Sato
Kazuya Asano
Takahiro Maeta
Akiko Yashima-Abo
Ryosei Sasaki
Yoshiaki Okano
Tatsuo Oyake
Shigeki Ito
机构
[1] Iwate Medical University,Hematology and Oncology, Department of Internal Medicine, School of Medicine
[2] Hachinohe Red Cross Hospital,Department of Hematology
[3] Iwate Medical University,Division of Biomedical Research & Development, Institute for Biomedical Sciences, School of Medicine
来源
International Journal of Hematology | 2023年 / 118卷
关键词
PD-1; Nivolumab; Refractory Hodgkin lymphoma; Nivolumab-free PD-1; irAE;
D O I
暂无
中图分类号
学科分类号
摘要
A 37-year-old man with refractory classical Hodgkin lymphoma (cHL) underwent PD-1 blockade therapy with nivolumab, which resulted in a partial response. However, treatment was discontinued due to immune-related adverse events (irAEs), including myasthenia gravis and myositis. Retreatment with nivolumab resulted in a complete metabolic response and hepatic irAE. Subsequently, nivolumab was administered at extended dosing intervals. Intermittent infusion of ten doses of nivolumab for a total dose of 2400 mg/body helped control the relapsed/refractory cHL over three years. During nivolumab treatment, disease progression and emergence of irAEs were associated with the proportion of CD8 + T cells expressing nivolumab-free PD-1 relative to the total number of CD8 + T cells. The findings in this nivolumab-sensitive patient highlight the clinical utility of monitoring immune cells expressing nivolumab-free PD-1 in patients with cHL who have been treated with nivolumab and have experienced irAEs.
引用
收藏
页码:751 / 757
页数:6
相关论文
共 126 条
[1]  
Younes A(2016)Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and Brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Lancet Oncol 17 1283-1294
[2]  
Santoro A(2020)Immune-related adverse events of checkpoint inhibitors Nat Rev Dis Primers 6 38-228
[3]  
Shipp M(2017)PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD Blood 130 221-3175
[4]  
Zinzani PL(2010)Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 3167-515
[5]  
Timmerman JM(2020)Moving towards personalized treatments of immune-related adverse events Nat Rev Clin Oncol 17 504-515
[6]  
Ansell S(2018)Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients JCI Insight 3 510-270
[7]  
Ramos-Casals M(2020)Monitoring PD-1-blocking antibodies bound to T cells derived from a drop of peripheral blood J Vis Exp 108 955-1439
[8]  
Brahmer JR(2018)Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma Int J Hematol 8 253-1026
[9]  
Callahan MK(2020)Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥ 2 immune-related adverse events in patients with cancer J Immunother Cancer 14 1428-1427
[10]  
Flores-Chávez A(2022)Safety of immune checkpoint inhibitor resumption after interruption for immune-related adverse events, a narrative review Cancers (Basel) 17 1021-3277